Effect of type-specific human papillomavirus incidence on screening performance and cost

International Journal of Gynecological Cancer

Volumn 20, Issue 2, 2010, Pages 276-282

  Agorastos, Theodoros ^a   Sotiriadis, Alexandros ^a   Emmanouilides, Christos J ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Colposcopy; Cytology; HPV; Hybrid capture; Screening

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC ERROR; EMERGENCY HEALTH SERVICE; FEMALE; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INCIDENCE; INFECTION RATE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS INFECTION; ECONOMICS; MASS SCREENING; PAPILLOMAVIRUS INFECTION; THEORETICAL MODEL; UTERINE CERVIX TUMOR; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INCIDENCE; MARKOV CHAINS; MASS SCREENING; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 77951916894     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181ca5df3     Document Type: Article

References (17)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
2. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527. (Pubitemid 36159887)
3. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000;283:87-93.
4. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589-1597.
5. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579-1588.
6. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100:492-501.
7. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virusYlike particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-1765.
8. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18:follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.
9. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virusYlike particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-278.
10. Ault KA. Effect of prophylactic human papillomavirus L1 virusYlike-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369:1861-1868.
11. Lehtinen M, Herrero R, Mayaud P, et al. Chapter 28:Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine. 2006;24: S233-S241.
12. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26: K29-K41.
13. Ronco G, Brezzi S, Carozzi F, et al. The New Technologies for Cervical Cancer screening randomised controlled trial. An overview of results during the first phase of recruitment. Gynecol Oncol. 2007;107: S230-232.
14. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, the Netherlands, France, and Italy. J Natl Cancer Inst. 2005;97:888-895.
15. Gravitt PE, Coutlee F, Iftner T, et al. New technologies in cervical cancer screening. Vaccine. 2008;26: K42-K52.
16. Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large populationYbased prospective study: the Manchester cohort. Br J Cancer. 2004;91:942-953.
17. Coupe VM, Berkhof J, Verheijen RH, et al. Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG. 2007;114:416-424. (Pubitemid 46393302)